MA40599A1 - Formulations injectables de paracétamol - Google Patents

Formulations injectables de paracétamol

Info

Publication number
MA40599A1
MA40599A1 MA40599A MA40599A MA40599A1 MA 40599 A1 MA40599 A1 MA 40599A1 MA 40599 A MA40599 A MA 40599A MA 40599 A MA40599 A MA 40599A MA 40599 A1 MA40599 A1 MA 40599A1
Authority
MA
Morocco
Prior art keywords
paracetamol
injectable formulations
intravenous
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MA40599A
Other languages
English (en)
Inventor
Ketan R Patel
Milan R Patel
Asheel K Patel
Prakashchandra J Shah
Original Assignee
Troikaa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55022620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40599(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Troikaa Pharmaceuticals Ltd filed Critical Troikaa Pharmaceuticals Ltd
Publication of MA40599A1 publication Critical patent/MA40599A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des injections intraveineuses à faible volume de paracétamol ou son sel pharmaceutiquement acceptable, et leur procédé de préparation. Les formulations fournissent une concentration élevée de paracétamol ou son sel pharmaceutiquement acceptable dans un système de solvant de la présente invention, qui peut être administrée non seulement par perfusion intraveineuse et intramusculaire, mais est également appropriée pour l'administration lente de bolus intraveineux après dilutio
MA40599A 2014-12-20 2015-11-17 Formulations injectables de paracétamol MA40599A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4102MU2014 2014-12-20
PCT/IB2015/058876 WO2016097899A1 (fr) 2014-12-20 2015-11-17 Formulations injectables de paracétamol

Publications (1)

Publication Number Publication Date
MA40599A1 true MA40599A1 (fr) 2017-11-30

Family

ID=55022620

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40599A MA40599A1 (fr) 2014-12-20 2015-11-17 Formulations injectables de paracétamol

Country Status (28)

Country Link
US (1) US20180000940A1 (fr)
EP (1) EP3233055A1 (fr)
JP (1) JP2017538762A (fr)
KR (1) KR20170099911A (fr)
CN (1) CN107205924A (fr)
AR (1) AR103188A1 (fr)
AU (1) AU2015365533A1 (fr)
BR (1) BR112017012975B1 (fr)
CA (1) CA2969303A1 (fr)
CL (1) CL2017001629A1 (fr)
CO (1) CO2017006268A2 (fr)
CU (1) CU20170088A7 (fr)
DO (1) DOP2017000134A (fr)
EA (1) EA201791409A1 (fr)
EC (1) ECSP17038668A (fr)
IL (1) IL252729A0 (fr)
JO (1) JO3689B1 (fr)
MA (1) MA40599A1 (fr)
MD (1) MD20170071A2 (fr)
MX (1) MX2017008264A (fr)
PE (1) PE20171305A1 (fr)
PH (1) PH12017501005A1 (fr)
SG (1) SG11201704435PA (fr)
TN (1) TN2017000232A1 (fr)
TW (1) TWI649097B (fr)
UA (1) UA122136C2 (fr)
UY (1) UY36466A (fr)
WO (1) WO2016097899A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107229455B (zh) 2016-03-24 2019-09-17 阿里巴巴集团控股有限公司 一种业务处理方法、装置及系统

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
IT1301976B1 (it) * 1998-07-31 2000-07-20 Angelini Ricerche Spa Composizione farmaceutica iniettabile a base di paracetamolo
IT1313579B1 (it) 1999-07-30 2002-09-09 Acraf Composizione farmaceutica liquida a base di paracetamolo.
ITMI20012135A1 (it) 2001-10-16 2003-04-16 Bioren S A Soluzioni iniettabili pronte all'uso di paracetamolo
MX2007014862A (es) * 2005-05-27 2008-02-21 Panacea Biotec Ltd Composiciones inyectables y procedimiento para la preparacion de dichas composiciones.
DK1973527T3 (da) * 2005-12-15 2010-02-01 Acusphere Inc Fremgangsmåder til fremstilling af partikelbaserede farmaceutiske formulationer til parenteral indgivelse
EP2170313A2 (fr) 2007-06-18 2010-04-07 Combino Pharm, S.L. Préparations aqueuses d'acétaminophène pour injection
WO2009098716A2 (fr) 2008-01-17 2009-08-13 Aptuit Laurus Private Limited Compositions pharmaceutiques aqueuses stables
CN102159184B (zh) * 2008-10-09 2013-09-04 方济各安吉利克化学联合股份有限公司 含有对乙酰氨基酚的液体药物制剂
BR112012031928B1 (pt) 2010-06-30 2021-08-31 Troikaa Pharmaceuticals Ltd Composições farmacêuticas as quais incluem paracetamol e processo para preparação do mesmo
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN102258485A (zh) * 2011-01-11 2011-11-30 北京润德康医药技术有限公司 一种含对乙酰氨基酚的注射用制剂及其应用
CN102600068A (zh) * 2011-01-24 2012-07-25 联康药业克雷恩特塞提斯制药实验室有限责任公司 稳定即用的可注射扑热息痛制剂

Also Published As

Publication number Publication date
CA2969303A1 (fr) 2016-06-23
CU20170088A7 (es) 2018-03-13
MX2017008264A (es) 2017-10-02
CN107205924A (zh) 2017-09-26
EP3233055A1 (fr) 2017-10-25
SG11201704435PA (en) 2017-06-29
WO2016097899A1 (fr) 2016-06-23
ECSP17038668A (es) 2017-12-01
KR20170099911A (ko) 2017-09-01
CL2017001629A1 (es) 2018-03-16
PH12017501005A1 (en) 2017-12-11
UY36466A (es) 2016-07-29
JP2017538762A (ja) 2017-12-28
JO3689B1 (ar) 2020-08-27
TW201622703A (zh) 2016-07-01
TWI649097B (zh) 2019-02-01
BR112017012975A2 (pt) 2018-02-27
TN2017000232A1 (en) 2018-10-19
IL252729A0 (en) 2017-08-31
UA122136C2 (uk) 2020-09-25
AR103188A1 (es) 2017-04-19
DOP2017000134A (es) 2017-09-15
PE20171305A1 (es) 2017-09-05
US20180000940A1 (en) 2018-01-04
MD20170071A2 (ro) 2017-09-30
AU2015365533A1 (en) 2017-07-06
BR112017012975B1 (pt) 2023-09-26
EA201791409A1 (ru) 2017-10-31
CO2017006268A2 (es) 2017-10-20

Similar Documents

Publication Publication Date Title
MX2021012050A (es) Formulaciones de proteinas liquidas que contienen agentes reductores de viscosidad.
JP2017519018A5 (fr)
EA033373B1 (ru) Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему
EA201790568A1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
AR102096A1 (es) Proceso para elaborar acetato de glatiramer
PH12015501373A1 (en) Injectable depot formulation comprising optically active tolvaptan and process of producing the same
HRP20200704T1 (hr) Vodena formulacija koja sadrži paracetamol i ibuprofen
FI3383385T4 (fi) Melflufeeniannoskuureja syöpään
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
MA40599A1 (fr) Formulations injectables de paracétamol
EA201291433A1 (ru) Содержащие парацетамол фармацевтические композиции и способ их получения
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MA37500B1 (fr) Formulation parentérale d'esmolol
RU2011133838A (ru) Способ повышения продуктивности свиней
RU2014147357A (ru) Применение l-карнитина в качестве средства снижения риска развития фатальной аритмии
RU2013143983A (ru) Способ коррекции иммунной недостаточности у инфицированного вирусом лейкоза крупного рогатого скота
RU2014142874A (ru) Способ лечения похмельного синдрома у лиц, не относящихся к больным алкоголизмом
RU2013133532A (ru) Способ лечения поражений центральной нервной системы неходжкинскими лимфомами
MA38007B1 (fr) Formulations liquides d'apixaban
TH169594A (th) สูตรผสมความเข้มข้นสูงของตัวรับ Fc ที่ละลายได้
RU2010141350A (ru) Способ иммунокоррекции у инфицированного вирусом лейкоза крупного рогатого скота